<DOC>
	<DOCNO>NCT02007954</DOCNO>
	<brief_summary>The purpose study determine feasibility safety use small bead ( 70-150 micron place 100-300 micron ) deliver chemotherapy liver treat patient hepatocellular carcinoma ( HCC ) . The bead ( LC-Bead M1 ) load doxorubicin ( DEBDOX-M1 ) , use administer transarterial chemoembolization ( TACE ) DEBDOX , load doxorubicin , device utilizes tiny bead ( 70-150 micron ) deliver chemotherapy agent liver tumor ( ) via hepatic artery . This device allow continuous release doxorubicin liver tumor tissue ( ) cause necrosis target tumor ( ) . The potential advantage small bead deep penetration tumor bed , avoid premature proximal occlusion vessel feed tumor , consistent dose . Response therapy evaluate monthly clinic visit blood test ( include assessment liver function tumor marker ) image ( usually MRIs ) every 1-2 month . Patients study 6 month exit study follow survival . Once exit study continue eligible receive small bead ( DEBDOX ) , recommend .</brief_summary>
	<brief_title>Doxorubicin-eluting LC Bead M1 Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . The patient preserve liver function ( ChildPugh AB class ) without significant liver decompensation . 2 . The patient Eastern Cooperative Oncology Group ( ECOG ) performance status 02 study entry . 3 . The patient age 18 year old . 4 . The patient life expectancy &gt; 12 week . 5 . The patient measurable evaluable disease directly treat intrahepatic therapy ( define Response Evaluation Criteria Solid Tumors [ RECIST ] 1.1 ) . 6 . The patient adequate hematologic function define follow criterion : An absolute neutrophil count ( ANC ) ≥ 1500/micro L , Hemoglobin ≥ 9.5 g/dL , Platelet count ≥ 50,000/micro L. 7 . The patient adequate hepatic function , define follow criterion : Total bilirubin &lt; /= 3.0 mg/dL Aspartate transaminase ( AST ) alanine transaminase ( ALT ) &lt; /= 8 x upper limit normal ( ULN ) . 8 . The patient adequate renal function , define follow criterion : Serum creatinine &lt; /= 2.0 x institutional ULN 9 . The patient baseline international normalize ratio ( INR ) &lt; 1.5 . 10 . The patient , woman childbearing potential , negative pregnancy test . 11 . The patient able give write informed consent . 12 . The patient willing able comply study procedure , schedule visit , treatment plan . 13 . Patients early stage HCC may include protocol receive DEBDOXM1 prior resection EXCLUSION CRITERIA : 1 . The patient history another primary cancer ( ie , primary cancer associate patient 's current liver tumor ) , exception ( ) curatively resect nonmelanomatous skin cancer ; ( b ) curatively treated cervical carcinoma situ ; ( c ) primary solid tumor treat curative intent , know active disease present , treatment administer last 3 year prior enrollment ( date inform consent ) . 2 . The patient receive concurrent treatment anticancer therapy , include chemotherapy , immunotherapy , hormonal therapy , radiotherapy , chemoembolization , target therapy , investigational agent . 3 . The patient extrahepatic , metastatic , symptomatic HCC . Enlarged reactive lymph node , indeterminate lesion , lung nodule acceptable . 4 . The patient 's tumor replace &gt; 70 % liver volume . 5 . The patient clinically significant ascites . Trace ascites image acceptable . 6 . Marcoshunting note hepatic angiogram . 7 . The patient untreatable bleeding diathesis . 8 . The patient complete main portal vein thrombosis reversal flow . 9 . The patient leave ventricle ejection fraction le 45 % . 10 . The patient evidence clinically significant peripheral vascular disease . 11 . The patient clinically significant symptomatic extrahepatic disease , example , uncontrolled intercurrent illness include , limited : Ongoing active infection require parenteral antibiotic Symptomatic congestive heart failure ( class II IV New York Heart Association classification heart disease ) Unstable angina pectoris , angioplasty , stenting , myocardial infarction within 6 month Uncontrolled hypertension ( systolic blood pressure &gt; 150 mmHg , diastolic blood pressure &gt; 90 mmHg , find 2 consecutive measurement separate 1week period despite adequate medical support ) Clinically significant cardiac arrhythmia ( multifocal premature ventricular contraction , bigeminy , trigeminy , ventricular tachycardia symptomatic require treatment [ NCICTCAE Grade 3 ] asymptomatic sustain ventricular tachycardia ) Psychiatric illness/social situation would compromise patient safety limit compliance study requirement 12 . There evidence substance abuse medical , psychological social condition may interfere patient 's participation study evaluation study result . 13 . The patient pregnant breastfeeding . 14 . The patient allergic contrast medium readily prevent premedication manage . 15 . The patient extrahepatic , metastatic , symptomatic HCC .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>HCC</keyword>
</DOC>